Daytrana Approval For Adolescents Gives Shire's ADHD Drug A New Lease On Life
This article was originally published in The Pink Sheet Daily
Sales of the patch were down 10 percent last year due to recalls caused by manufacturing problems.
You may also be interested in...
FDA says that Intuniv patient materials claimed it treats such non-ADHD behavioral problems as temper outbursts.
HHS' request for documents comes as Shire launches new marketing campaigns and co-promotion with GlaxoSmithKline.
FDA's spate of five promotional citations to manufacturers of attention deficit/hyperactivity disorder drugs signals that the agency intends to remain vigilant in oversight of new media